Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | RXRA | P19793 | 3/20 | 0.49 |
| ▸ | RXRB | P28702 | 2/20 | 0.49 |
| ▸ | RXRG | P48443 | 2/20 | 0.49 |
| ▸ | NQO1 | P15559 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.47 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.47 |
| ▸ | HNF4A | P41235 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860140 | 0.85 | PPARG (0.56) | PPARGRXRARXRBRXRGCYP3A4 | |
| SCHEMBL23446783 | 0.82 | PPARG (0.47) | PPARGRXRARXRBRXRGCYP3A4 | |
| SCHEMBL5960357 | 0.81 | PPARG (0.49) | PPARGRXRARXRBRXRGCYP3A4 | |
| SCHEMBL16993773 | 0.79 | RXRA (0.69) | PPARGRXRARXRBRXRGCYP3A4 | |
| SCHEMBL24084727 | 0.78 | PPARG (0.44) | PPARGRXRARXRBRXRGCYP3A4 | |
| SCHEMBL4420031 | 0.78 | RXRA (0.53) | PPARGRXRARXRBRXRGCYP3A4 | |
| SCHEMBL29462816 | 0.78 | RXRA (0.53) | PPARGRXRARXRBRXRGCYP3A4 | |
| SCHEMBL9551756 | 0.77 | CYP3A4 (0.58) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL10646081 | 0.75 | RARG (0.67) | RXRARXRBRXRGCYP3A4CYP26A1 | |
| SCHEMBL10646080 | 0.75 | RARG (0.67) | RXRARXRBRXRGCYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019034-B2 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | ALLERGAN, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040147611-A1 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | ALLERGAN, INC. | 2004-07-29 | — | — | US | disclosed |
| US-5439925-A | Skin disorders, rheumatic diseases | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147611-A1 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | RXRA, RXRB, RXRG | PPARG 24/4885RXRA 1/4885RXRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.